APP and memory impairment: Consistent with these findings, administration of the GIPR-GLP-1R co-agonist DA4-JC (10 nmol/kg/day) for 8 weeks was more effective in reversing memory impairment and decreasing amyloid plaque accumulation and neuroinflammation, relative to findings obtained with equimolar dosing of liraglutide in 9-month-old male and female APP/PS1 mice [27].